AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28964736 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab in APOB-defective heterozygotes
Number of subjects: 1191
Study 28964736 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab in PCSK9 heterozygotes
Number of subjects: 1191
Study 28964736 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab in patients with no identified mutations
Number of subjects: 1191
Study 28964736 — intervention group
Group type: COMPARATOR
Intervention: Alirocumab
Number of subjects: 1191
Study 28964826 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistance concentric-eccentric training (HHH) 3d/week
Number of subjects: 64
Study 28964826 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistance training (HH) 2d/week
Number of subjects: 64
Study 28964826 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed model (HLH) 3d/week consisting of H training 2d/week and 1 bout of low-resistance, high-velocity, concentric only training
Number of subjects: 64
Study 28964826 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed model (HL) 2d/week consisting of H training 1d/week and L training 1d/week
Number of subjects: 64
Study 28965093 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive treatment for hypertension (antihypertensive medication)
Number of subjects: 10003
Study 28965093 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive treatment for dyslipidaemia (statin)
Number of subjects: 10003
Study 28965093 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive treatment for diabetes (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker)
Number of subjects: 10003
Study 28965093 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle factors (sedentary behavior)
Number of subjects: 10003
Study 28965093 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle factors (smoking)
Number of subjects: 10003
Study 28965093 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle factors (obesity)
Number of subjects: 10003
Study 28965093 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment gap in dyslipidaemia
Number of subjects: 10003
Study 28965106 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB treatment
Number of subjects: 168
Study 28965185 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdafitinib 2, 4, or 6 mg daily dosing schedule
Number of subjects: 19
Study 28965185 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdafitinib 10 mg or 12 mg intermittent dosing schedule
Number of subjects: 19
Study 28965185 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdafitinib (all doses)
Number of subjects: 19
Study 28965778 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 0
Study 28965778 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28966645 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal concentrations of melatonin, GABA, and total antioxidants in peripheral blood (insomnia group)
Number of subjects: 75
Study 28966645 — intervention group
Group type: COMPARATOR
Intervention: Nocturnal concentrations of melatonin, GABA, and total antioxidants in peripheral blood (non-insomnia group)
Number of subjects: 75
Study 28966645 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of stroke (insomnia group)
Number of subjects: 75
Study 28966645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index, Insomnia Severity Index, Epworth Sleepiness Scale, Fatigue Severity Scale, Morningness-Eveningness Questionnaire (Chinese version), National Institute of Health Stroke Scale (insomnia group)
Number of subjects: 75
Study 28966645 — intervention group
Group type: COMPARATOR
Intervention: Pittsburgh Sleep Quality Index, Insomnia Severity Index, Epworth Sleepiness Scale, Fatigue Severity Scale, Morningness-Eveningness Questionnaire (Chinese version), National Institute of Health Stroke Scale (non-insomnia group)
Number of subjects: 75
Study 28967387 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteriologic criterion of ≥10,000 colony forming units/mL of a single organism
Number of subjects: 0
Study 28967387 — intervention group
Group type: EXPERIMENTAL
Intervention: Properly collected urine
Number of subjects: 0
Study 28968874 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted influenza A/California/7/2009 (pH1N1) vaccine
Number of subjects: 92
Study 28968971 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel surgical method for intraoperative precise sentinel lymph node biopsy (SLNB) guided by lymphatic drainage
Number of subjects: 125
Study 28969597 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation
Number of subjects: 12
Study 28970100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive training with functional electrical stimulation for 1 hour per day, 5 days per week for 8 weeks.
Number of subjects: 70
Study 28970100 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus three 15-minute sessions per week of one-to-one hand therapy without functional electrical stimulation.
Number of subjects: 70
Study 28970161 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with colistin (9 million UI/day) and tigecycline (100 mg/day)
Number of subjects: 118
Study 28970161 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with colistin (9 million UI/day)
Number of subjects: 118
Study 28970161 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with colistin and tigecycline
Number of subjects: 118
Study 28970161 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical therapy with colistin
Number of subjects: 118
Study 28970161 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal dysfunction before treatment
Number of subjects: 118
Study 28970192 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based stress management with minimal contact (iCBT)
Number of subjects: 0
Study 28970192 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management with face-to-face interviews (CBT)
Number of subjects: 0
Study 28970192 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group (WLC)
Number of subjects: 0
Study 28970202 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial resistance exercise (M-Ex)
Number of subjects: 11
Study 28970202 — intervention group
Group type: COMPARATOR
Intervention: No exercise (NoEx)
Number of subjects: 11
Study 28970332 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessments of fundic accommodation by trained readers (nuclear medicine and radiology physicians) during solid-meal gastric emptying scintigraphy (GES)
Number of subjects: 0
Study 28970332 — intervention group
Group type: EXPERIMENTAL
Intervention: Software developed to quantify intragastric meal distribution (IMD) during GES
Number of subjects: 0
Study 28970332 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric emptying measurements
Number of subjects: 0
Study 28970513 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cholesterol efflux/apoA-I quartile
Number of subjects: 462
Study 28970513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol efflux/apoA-I ratio
Number of subjects: 462
Study 28970956 — intervention group
Group type: EXPERIMENTAL
Intervention: R-Y reconstruction using two circular staplers
Number of subjects: 118
Study 28970956 — intervention group
Group type: COMPARATOR
Intervention: B-I reconstruction
Number of subjects: 118
Study 28971097 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron- and zinc-biofortified pearl millet (FeZnPM)
Number of subjects: 0
Study 28971097 — intervention group
Group type: COMPARATOR
Intervention: Conventional pearl millet (CPM)
Number of subjects: 0
Study 28971223 — intervention group
Group type: EXPERIMENTAL
Intervention: Index offspring (offspring of women with type 1 diabetes)
Number of subjects: 581
Study 28971223 — intervention group
Group type: COMPARATOR
Intervention: Control offspring
Number of subjects: 581
Study 28971850 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28971851 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28971861 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin; specific dosage and duration not mentioned.
Number of subjects: 0
Study 28971900 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib 100 mg once daily until progression, intolerance, or withdrawal of consent
Number of subjects: 72
Study 28971900 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib 100 mg once daily
Number of subjects: 72
Study 28972002 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac myosin-binding protein C (cMyC)
Number of subjects: 1954
Study 28972002 — intervention group
Group type: COMPARATOR
Intervention: High-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 1954
Study 28972002 — intervention group
Group type: COMPARATOR
Intervention: High-sensitivity cardiac troponin I (hs-cTnI)
Number of subjects: 1954
Study 28972011 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral leniolisib (CDZ173)
Number of subjects: 6
Study 28972913 — intervention group
Group type: EXPERIMENTAL
Intervention: WTCHR group
Number of subjects: 402
Study 28972913 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 402
Study 28973026 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum phosphate
Number of subjects: 3226
Study 28973026 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum phosphate in patients older than 65 years
Number of subjects: 3226
Study 28973026 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum phosphate in patients on dialysis more than one year
Number of subjects: 3226
Study 28973026 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum phosphate in patients with serum albumin lower than 3.9 g/dL
Number of subjects: 3226
Study 28973091 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement with the SAPIEN 3 valve
Number of subjects: 1661
Study 28973164 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Number of subjects: 12
Study 28973164 — intervention group
Group type: COMPARATOR
Intervention: Isoglycemic Intravenous Glucose Infusion (IIGI)
Number of subjects: 12
Study 28973223 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (5.6 hours sleep/24 hours) with circadian disruption (recurring 28-hour 'day' in dim light) for 3 weeks
Number of subjects: 10
Study 28973223 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction with circadian disruption
Number of subjects: 10
Study 28973403 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilotumumab monotherapy (10 or 20 mg/kg IV every 2 weeks)
Number of subjects: 21
Study 28973403 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilotumumab in combination with cisplatin (80 mg/m2 on Day 1) and capecitabine (1000 mg/m2 twice daily on Days 1-14 of every 21-day cycle)
Number of subjects: 21
Study 28973403 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events related to any treatment
Number of subjects: 21
Study 28973403 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-limiting toxicities (DLTs)
Number of subjects: 21
Study 28973520 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR), n=321
Number of subjects: 2795
Study 28973520 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR), n=313
Number of subjects: 2795
Study 28973520 — intervention group
Group type: COMPARATOR
Intervention: TAVR vs medical treatment, n=165
Number of subjects: 2795
Study 28973520 — intervention group
Group type: COMPARATOR
Intervention: Continued access observational studies (TAVR), n=1996
Number of subjects: 2795
Study 28973622 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/d of biotin supplementation for 7 days
Number of subjects: 6
Study 28973622 — intervention group
Group type: COMPARATOR
Intervention: Nonbiotinylated assays (14 assays)
Number of subjects: 6
Study 28973622 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotinylated competitive immunoassays
Number of subjects: 6
Study 28973622 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotinylated sandwich immunoassays
Number of subjects: 6
Study 28974059 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented pulse pressure variation (PPV12) induced by 2-min ventilation with a tidal volume (V T ) of 12 ml kg -1
Number of subjects: 38
Study 28974059 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard pulse pressure variation (PPV8) with a tidal volume of 8 ml kg -1
Number of subjects: 38
Study 28974067 — intervention group
Group type: EXPERIMENTAL
Intervention: High inspiratory oxygen fraction (FIO2)
Number of subjects: 73922
Study 28974067 — intervention group
Group type: COMPARATOR
Intervention: Low inspiratory oxygen fraction (FIO2)
Number of subjects: 73922
Study 28974209 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated voice messages about contraception sent to mobile phones (11 messages over 4 months)
Number of subjects: 960
Study 28974209 — intervention group
Group type: COMPARATOR
Intervention: Usual clinic care including contraceptive counselling and call centre access
Number of subjects: 960
Study 28974224 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline externalizing behavior T-score (higher externalizing behavior) among boys
Number of subjects: 524
Study 28974224 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline externalizing behavior T-score (higher externalizing behavior) among girls
Number of subjects: 524
Study 28974230 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrified embryos
Number of subjects: 286
Study 28974230 — intervention group
Group type: COMPARATOR
Intervention: Slow frozen embryos
Number of subjects: 286
Study 28974230 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact embryos
Number of subjects: 286
Study 28974230 — intervention group
Group type: COMPARATOR
Intervention: Not intact embryos
Number of subjects: 286
Study 28974464 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of any kind
Number of subjects: 107
Study 28974464 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of plants
Number of subjects: 107
Study 28974464 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of persons
Number of subjects: 107
Study 28974483 — intervention group
Group type: EXPERIMENTAL
Intervention: SmokefreeMOM (automated smoking cessation text-messaging program)
Number of subjects: 99
Study 28974483 — intervention group
Group type: EXPERIMENTAL
Intervention: SmokefreeMOM
Number of subjects: 99
Study 28974483 — intervention group
Group type: COMPARATOR
Intervention: Control (quitline referral)
Number of subjects: 99
Study 28974486 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training plus beetroot (EX+BR)
Number of subjects: 30
Study 28974486 — intervention group
Group type: COMPARATOR
Intervention: Exercise training plus placebo (EX+PL)
Number of subjects: 30
Study 28974506 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 58
Study 28974506 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin + consolidative stem cell transplant (SCT)
Number of subjects: 58
Study 28975039 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative music therapy (CMT), approximately 20 minutes duration, three times per week, delivered by a trained music therapist singing in lullaby style, adjusted to the infant's rhythm and affect.
Number of subjects: 60
Study 28975039 — intervention group
Group type: COMPARATOR
Intervention: Standard care with CMT.
Number of subjects: 60
Study 28975039 — intervention group
Group type: COMPARATOR
Intervention: Standard neonatal intensive care.
Number of subjects: 60
Study 28975040 — intervention group
Group type: EXPERIMENTAL
Intervention: Small volume plasma exchange (SVPE)
Number of subjects: 20
Study 28975084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-Etoposide (CE)
Number of subjects: 346
Study 28975084 — intervention group
Group type: COMPARATOR
Intervention: Ifosfamide + Etoposide + Epirubicin (IVE)
Number of subjects: 346
Study 28976050 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Speckle Contrast Imaging with mouth constantly open
Number of subjects: 70
Study 28976050 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Speckle Contrast Imaging with lip retraction
Number of subjects: 70
Study 28976050 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Speckle Contrast Imaging with alternating direct and indirect imaging
Number of subjects: 70
Study 28976556 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR260301 (100 mg to 440 mg once daily)
Number of subjects: 21
Study 28976817 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenti-D gene therapy (autologous CD34+ cells transduced with elivaldogene tavalentivec)
Number of subjects: 17
Study 28976817 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenti-D gene therapy
Number of subjects: 17
Study 28977361 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 442
Study 28977361 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (unoperated)
Number of subjects: 442
Study 28977548 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracic surgery (VATS)
Number of subjects: 31
Study 28977548 — intervention group
Group type: COMPARATOR
Intervention: Postero-lateral thoracotomy (PLT)
Number of subjects: 31
Study 28977630 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited cutaneous systemic sclerosis (lcSSc)
Number of subjects: 334
Study 28977630 — intervention group
Group type: EXPERIMENTAL
Intervention: Antinuclear antibodies (ACA)
Number of subjects: 334
Study 28977630 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 334
Study 28977630 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening of dyspnoea
Number of subjects: 334
Study 28977630 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HAQ-DI
Number of subjects: 334
Study 28977630 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 334
Study 28977630 — intervention group
Group type: EXPERIMENTAL
Intervention: Active finger ulceration
Number of subjects: 334
Study 28977630 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary incontinence (UI)
Number of subjects: 334
Study 28978139 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CVP (rituximab, cyclophosphamide, vincristine, and prednisolone)
Number of subjects: 33
Study 28978306 — intervention group
Group type: EXPERIMENTAL
Intervention: 4D PET-CT
Number of subjects: 15
Study 28978306 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D PET-CT
Number of subjects: 15
Study 28978306 — intervention group
Group type: EXPERIMENTAL
Intervention: 4D CT
Number of subjects: 15
Study 28978306 — intervention group
Group type: EXPERIMENTAL
Intervention: 4D CT with co-registered 3D PET
Number of subjects: 15
Study 28978463 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited screening strategy
Number of subjects: 392
Study 28978463 — intervention group
Group type: COMPARATOR
Intervention: Limited screening and FDG PET/CT
Number of subjects: 392
Study 28978527 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic life support plus advanced life support response
Number of subjects: 5572
Study 28978527 — intervention group
Group type: COMPARATOR
Intervention: Emergency medical services only (control)
Number of subjects: 5572
Study 28978540 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional vitamin B-6 status
Number of subjects: 0
Study 28978547 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubly labeled water (DLW) method
Number of subjects: 0
Study 28978551 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I testing in patients with renal impairment
Number of subjects: 4726
Study 28978551 — intervention group
Group type: COMPARATOR
Intervention: High-sensitivity cardiac troponin I testing in patients without renal impairment
Number of subjects: 4726
Study 28978551 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with renal impairment and elevated cardiac troponin concentrations
Number of subjects: 4726
Study 28978797 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 375 mg per day for 28 days
Number of subjects: 12
Study 28978801 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (5,000 IU cholecalciferol daily for 90 days)
Number of subjects: 0
Study 28979661 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol Mebutate Gel 0.015%
Number of subjects: 0
Study 28979661 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28980004 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin 1.8 mg/kg infused over 30 minutes every 21 days
Number of subjects: 12
Study 28980198 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX) 70 mg/day
Number of subjects: 1013
Study 28980198 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic-release oral system methylphenidate (OROS-MPH) 72 mg/day
Number of subjects: 1013
Study 28980198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1013
Study 28980198 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX)
Number of subjects: 1013
Study 28980198 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic-release oral system methylphenidate (OROS-MPH)
Number of subjects: 1013
Study 28980198 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX) and OROS-MPH
Number of subjects: 1013
Study 28980204 — intervention group
Group type: EXPERIMENTAL
Intervention: DFCAT model
Number of subjects: 0
Study 28980394 — intervention group
Group type: COMPARATOR
Intervention: HDV RNA-positive patients
Number of subjects: 1267
Study 28980442 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated prostate radiotherapy
Number of subjects: 0
Study 28980442 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical tool for determining patient eligibility
Number of subjects: 0
Study 28980446 — intervention group
Group type: EXPERIMENTAL
Intervention: BIVV009 (60 mg/kg, 4 weekly doses)
Number of subjects: 10
Study 28980462 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranger paclitaxel-coated balloon angioplasty
Number of subjects: 172
Study 28980942 — intervention group
Group type: EXPERIMENTAL
Intervention: N + WSH intervention arm
Number of subjects: 662
Study 28980942 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 662
Study 28981385 — intervention group
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec plus ipilimumab
Number of subjects: 0